We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Monoclonal Antibody Blocks Development of Type I Diabetes in Mouse Model

By LabMedica International staff writers
Posted on 17 Jun 2015
Print article
Monoclonal antibody treatment prevented development of type I diabetes in a mouse model of the disease.

Type 1 diabetes is caused by an autoimmune reaction that destroys the pancreatic beta cells that produce insulin. The disease, which is currently treated by lifetime injections of insulin, is marked by pathologically elevated levels of sugar in the blood and urine that cause high rates of morbidity and mortality.

Investigators at The Hebrew University of Jerusalem (Israel) had previously identified a link between development of type I diabetes and the NKp46 receptor on the surface of NK (natural killer) immune cells. The NKp46 receptor is a member of the primary activating receptors of NK cells. This receptor was shown to recognize pancreatic beta cells, leading to their destruction by the immune system.

In the current study the investigators evaluated the potential therapeutic use of a monoclonal antibody intended to block the NKp46 receptor. They reported in the February 26, 2015, online edition of the journal PLoS One that their NCR1.15 antibody recognized the mouse homologue protein of NKp46, named Ncr1, and was able to down-regulate the surface expression of the NKp46 receptor on primary murine NK cells following antibody injection in vivo. Additionally, NCR1.15 treatments were able to down-regulate cytotoxic activity mediated by NKp46, but not by other NK receptors.

The investigators examined type I diabetes development in two models, non-obese diabetic mice and mice with a model of diabetes caused by low-dose streptozotocin. Results showed a significantly lower incidence of diabetic mice in the NCR1.15-treated group compared to control groups.

The Hebrew University of Jerusalem has signed an exclusive license agreement with the clinical-stage biopharmaceutical company BioLineRx (Jerusalem, Israel) to develop and commercialize the drug BL-9020 (NCR1.15) for the treatment of type I diabetes.

Related Links:
The Hebrew University of Jerusalem
BioLineRx


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Toxoplasma Gondii Test
Toxo IgG ELISA Kit
New
Malaria Rapid Test
OnSite Malaria Pf/Pan Ag Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.